GSK Ends PPAR-Gamma Diabetes Development, Studying New Indications
Executive Summary
GlaxoSmithKline will explore new indications for the PPAR-gamma agent GI-262,570 after terminating development of the compound for type 2 diabetes, the company told a third-quarter earnings call Oct. 23.